REstoring myocardial repair capacity via the modulation of MAcrophage mediated c...
REstoring myocardial repair capacity via the modulation of MAcrophage mediated cytoKINe secretion.
Type-2 diabetes (T2D) is a chronic condition strongly associated with cardiovascular diseases, mainly recurrent myocardial infarctions (MI), and generating enormous healthcare cost. Macrophages orchestrate the remodelling of the h...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2008-02161
FISIOPATOLOGIA DE LA INFILTRACION CARDIACA. PAPEL DE LOS MAC...
327K€
Cerrado
PID2021-122941OB-I00
MODULACION DE LA INFLAMACION Y EL METABOLISMO CARDIACO PARA...
206K€
Cerrado
CardiacStroma
Tissue Cytokines at the Nexus of Immune Cell Cardiac Stroma...
2M€
Cerrado
JDC2023-052120-I
Relevancia de Orai1 en la respuesta inflamatoria tras infart...
72K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Type-2 diabetes (T2D) is a chronic condition strongly associated with cardiovascular diseases, mainly recurrent myocardial infarctions (MI), and generating enormous healthcare cost. Macrophages orchestrate the remodelling of the heart post-MI by efferocytosis-mediated cytokine secretion. Specifically, Mertk-mediated efferocytosis promotes vessel formation, tissue reperfusion and resolution of the inflammatory response via the secretion of the anti-inflammatory cytokines interleukin-10 (IL-10) and Vascular Endothelial Growth Factor-A (VEGF-A). In IR/T2D, efferocytosis-mediated cytokine secretion is impaired, leading to chronic inflammation, adverse post-MI remodelling, recurrent heart failure and excessive mortality. To date, the signalling and intracellular trafficking pathways leading to cytokines secretion are unknown, and the mechanisms of impairment during IR/T2D are unexplored. Previous therapeutic strategies focussed on repairing damaged tissue by injection of progenitor cells or modulating inflammation by cytokine injection, but both strategies gave disappointing results. In this proposal, I will define the mechanisms of efferocytosis-mediated cytokine secretion in macrophages, investigate their defects in IR/T2D and test a novel cell-based therapeutic strategy for improving recovery of T2D patients post-MI and preventing recurrence of cardiac events by restoring cytokine secretion in diabetic macrophages.